Infectious Disease

J&J vaccine offers permanent immunity, even against variants

Source / information

Published by:

Disclosure:
Barouch claims to be a co-inventor of related vaccine patents. Please refer to the study for all relevant financial information from the other authors.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

The data, now published in a major journal, shows that Johnson & Johnson’s COVID-19 vaccine produced potent activity against SARS-CoV-2, including variants of worrying, for at least 8 months.

The results were published in correspondence in the New England Journal of Medicine today, several weeks after Johnson & Johnson published them in a press release and the researchers posted them to a preprint server.

Vial of COVID19 vaccine

Johnson & Johnson’s COVID-19 vaccine elicits permanent reactions for at least 8 months, including against SARS-CoV-2 variants.
Source: Adobe Stock.

In the newspaper, Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School and colleagues report the 8-month duration of humoral and cellular immune responses in 20 people who received the Johnson & Johnson vaccine all in one have or two doses and five people who received a placebo.

According to the study, they evaluated the antibody and T-cell responses of 10 people 8 months after receiving a single dose of the vaccine and 10 people 6 months after receiving two doses. They also tested the performance of the vaccine against SARS-CoV-2 wild type and the Alpha (B.1.1.7), Kappa (B.1.617.1), Delta (B.1.617.2), Gamma (P. 1) , Epsilon (B.1.429) and Beta (B.1.351) variants.

Barouch and colleagues reported that antibody responses were detected in all vaccine recipients on day 239, with the median binding antibody titer against the wild-type SARS-CoV-2 receptor binding domain reaching 645 on day 29, 1,772 on day 57, 1,962 on day 71 and 1,306 on day 239. The median WA1 / 2020 pseudovirus neutralizing antibody titer was 272 on day 29, 169 on day 57, 340 on day 71, and 192 on day 239, and the titers were similar when the analyzes were limited to the participants had received the single-shot vaccination schedule, the researchers said.

In addition, the study found that three vaccine recipients had large increases in antibody responses during the study period, including one with a breakthrough infection that was “minimally symptomatic” and two who received a messenger RNA vaccine. Exclusion of these participants indicated that antibody responses were relatively stable over the 8 month period, with a decrease in median neutralizing antibody titer by a factor of 1.8 between the peak response on day 71 and the time at which the shelf life was assessed on day 239, Barouch and colleagues said.

According to the study, recipients who received a dose had a median neutralizing antibody titre of 184 against the wild strain, 158 against the D614G variant, 147 against the alpha variant, 171 against the kappa variant, 107 against the delta variant, 129 against the gamma variant, 87 against the epsilon variant, and 62 against the beta variant on day 239. The researchers said that these data indicate an “expansion of the neutralizing antibody range” that is associated with improved coverage of SARS-CoV- 2 variants are linked over time, including increased neutralizing antibody titers against these worrying variants.

“These data show that the Ad26.COV2.S vaccine elicited sustained humoral and cellular immune responses with minimal decreases for at least 8 months after immunization,” they wrote. “The durability of humoral and cellular immune responses after the Ad26.COV2.S vaccination with increased neutralizing antibody reactions to SARS-CoV-2 variants over time, even after a single vaccination, further supports the use of the Ad26.COV2.S vaccine . to fight the global COVID-19 pandemic. “

perspective

Back to top
Amesh A. Adalja, MD, FIDSA, FACP, FACEP)

Amesh A. Adalja, MD

With all of the booster talk, it’s becoming increasingly clear that the current vaccine crop offers lasting immunity. It is important to understand that immunity is more than just antibodies, it also involves T cells. Such robust immunity extends to problematic variants and provides protection against COVID-19, especially the consequences that really matter: serious illness, hospitalization and death. I suspect we will find that this immunity lasts long and will keep the majority of those vaccinated free from severe COVID-19 worries for a considerable period of time.

Amesh A. Adalja, MD

Senior scholarship holder

Johns Hopkins Center for Health Safety

Disclosure: Adalja does not report any relevant financial information.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles